Literature DB >> 20107314

OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins.

Hossein A Hamed1, Adly Yacoub, Margaret A Park, Patrick Eulitt, Devanand Sarkar, Igor P Dimitrie, Ching-Shih Chen, Steven Grant, David T Curiel, Paul B Fisher, Paul Dent.   

Abstract

The present studies focused on determining whether the autophagy-inducing drug OSU-03012 (AR-12) could enhance the toxicity of recombinant adenoviral delivery of melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) in glioblastoma multiforme (GBM) cells. The toxicity of a recombinant adenovirus to express MDA-7/IL-24 (Ad.mda-7) was enhanced by OSU-03012 in a diverse panel of primary human GBM cells. The enhanced toxicity correlated with reduced ERK1/2 phosphorylation and expression of MCL-1 and BCL-XL, and was blocked by molecular activation of ERK1/2 and by inhibition of the intrinsic, but not the extrinsic, apoptosis pathway.  Both OSU-03012 and expression of MDA-7/IL-24 increased phosphorylation of PKR-like endoplasmic reticulum kinase (PERK) that correlated with increased levels of autophagy and expression of dominant negative PERK blocked autophagy induction and tumor cell death. Knockdown of ATG5 or Beclin1 suppressed OSU-03012 enhanced MDA-7/IL-24-induced autophagy and blocked the lethal interaction between the two agents. Ad.mda-7-infected GBM cells secreted MDA-7/IL-24 into the growth media and this conditioned media induced expression of MDA-7/IL-24 in uninfected GBM cells. OSU-03012 interacted with conditioned media to kill GBM cells and knockdown of MDA-7/IL-24 in these cells suppressed tumor cell killing. Collectively, our data demonstrate that the induction of autophagy and mitochondrial dysfunction by a combinatorial treatment approach represents a potentially viable strategy to kill primary human GBM cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107314      PMCID: PMC2888700          DOI: 10.4161/cbt.9.7.11116

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  45 in total

1.  OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.

Authors:  Adly Yacoub; Margaret A Park; David Hanna; Young Hong; Clint Mitchell; Aditi P Pandya; Hisashi Harada; Garth Powis; Ching-Shih Chen; Costas Koumenis; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2006-04-18       Impact factor: 4.436

Review 2.  Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.

Authors:  Paul B Fisher; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Pankaj Gupta; Moira Sauane; Zao-zhong Su; Steven Grant; Paul Dent; David T Curiel; Neil Senzer; John Nemunaitis
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-23       Impact factor: 4.219

3.  BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis.

Authors:  Pankaj Gupta; Mark R Walter; Zao-zhong Su; Irina V Lebedeva; Luni Emdad; Aaron Randolph; Kristoffer Valerie; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2.

Authors:  Z-Z Su; I V Lebedeva; D Sarkar; L Emdad; P Gupta; S Kitada; P Dent; J C Reed; P B Fisher
Journal:  Oncogene       Date:  2006-04-13       Impact factor: 9.867

Review 5.  Is mda-7/IL-24 a "magic bullet" for cancer?

Authors:  Paul B Fisher
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

6.  mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.

Authors:  Sunil Chada; Dora Bocangel; Rajagopal Ramesh; Elizabeth A Grimm; John B Mumm; Abner M Mhashilkar; Mingzhong Zheng
Journal:  Mol Ther       Date:  2005-05       Impact factor: 11.454

Review 7.  Therapeutic advances for glioblastoma multiforme: current status and future prospects.

Authors:  H Ian Robins; Susan Chang; Nicholas Butowski; Minesh Mehta
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

8.  Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells.

Authors:  Adly Yacoub; Margaret A Park; Pankaj Gupta; Mohammed Rahmani; Guo Zhang; Hossein Hamed; David Hanna; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Moira Sauane; Nicollaq Vozhilla; Sarah Spiegel; Costas Koumenis; Martin Graf; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

9.  Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling.

Authors:  Adly Yacoub; Pankaj Gupta; Margaret A Park; Mohammed Rhamani; Hossein Hamed; David Hanna; Guo Zhang; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Costas Koumenis; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

Review 10.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310

View more
  24 in total

Review 1.  Regulation and function of autophagy during cell survival and cell death.

Authors:  Gautam Das; Bhupendra V Shravage; Eric H Baehrecke
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-06-01       Impact factor: 10.005

2.  Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines.

Authors:  Xin-Bo Xue; Chao-Wen Xiao; Hui Zhang; Ai-Guo Lu; Wei Gao; Zhu-Qing Zhou; Xin-Lai Guo; Ming-An Zhong; Yao Yang; Cong-Jun Wang
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 3.  The development of MDA-7/IL-24 as a cancer therapeutic.

Authors:  Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Xiang-Yang Wang; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zhao-zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej S Lesniak; Steven Grant; David T Curiel; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2010-08-21       Impact factor: 12.310

Review 4.  MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.

Authors:  Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zhao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej Lesniak; Steven Grant; David T Curiel; Paul B Fisher
Journal:  Anticancer Drugs       Date:  2010-09       Impact factor: 2.248

5.  The role of autophagy as a mechanism of cytotoxicity by the clinically used agent MDA-7/IL-24.

Authors:  Stacey Lehman; Constantinos Koumenis
Journal:  Cancer Biol Ther       Date:  2010-04-01       Impact factor: 4.742

6.  Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.

Authors:  Gabriele Di Sante; Timothy G Pestell; Mathew C Casimiro; Sara Bisetto; Michael J Powell; Michael P Lisanti; Carlos Cordon-Cardo; Mireia Castillo-Martin; Dennis M Bonal; Valentina Debattisti; Ke Chen; Liping Wang; Xiaohong He; Michael W McBurney; Richard G Pestell
Journal:  Am J Pathol       Date:  2015-01       Impact factor: 4.307

7.  Pancreatic cancers require autophagy for tumor growth.

Authors:  Shenghong Yang; Xiaoxu Wang; Gianmarco Contino; Marc Liesa; Ergun Sahin; Haoqiang Ying; Alexandra Bause; Yinghua Li; Jayne M Stommel; Giacomo Dell'antonio; Josef Mautner; Giovanni Tonon; Marcia Haigis; Orian S Shirihai; Claudio Doglioni; Nabeel Bardeesy; Alec C Kimmelman
Journal:  Genes Dev       Date:  2011-03-15       Impact factor: 11.361

8.  Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.

Authors:  Patrick J Eulitt; Margaret A Park; Hamed Hossein; Nichola Cruikshanks; Chen Yang; Igor P Dmitriev; Adly Yacoub; David T Curiel; Paul B Fisher; Paul Dent
Journal:  Cancer Biol Ther       Date:  2010-12-15       Impact factor: 4.742

Review 9.  Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.

Authors:  Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

10.  Melanoma Differentiation-associated Gene 7/IL-24 Exerts Cytotoxic Effects by Altering the Alternative Splicing of Bcl-x Pre-mRNA via the SRC/PKCδ Signaling Axis.

Authors:  Brian A Shapiro; Ngoc T Vu; Michael D Shultz; Jacqueline C Shultz; Jennifer A Mietla; Mazen M Gouda; Adly Yacoub; Paul Dent; Paul B Fisher; Margaret A Park; Charles E Chalfant
Journal:  J Biol Chem       Date:  2016-08-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.